Health officials are seeking to stretch supplies with lower doses, and to expand the vaccination pool beyond known patient contacts.
After the worst-ever week of new infections in one of the deadliest Ebola outbreaks in history, there is growing concern that the Canadian-developed Ebola vaccine is still mistrusted by many of the most vulnerable people in the crisis zone.
Of more than 90,000 people who were vaccinated, only 71 went on to develop Ebola. Fifty-six of those people developed symptoms fewer than 10 days after being vaccinated, suggesting the vaccine had not yet had time to fully protect them.
An antibody taken from an Ebola survivor has been found to target all three human strains of the virus and could eventually lead to an all-purpose vaccine.
Vaccine development for challenging diseases like Ebola and Marburg viruses remains a very difficult task. The pace at which the rVSV-ZEBOV vaccine has been developed and implemented, in addition to the effectiveness of the ring vaccination strategy, has paved a way for dealing with future outbreaks.
The World Health Organization (WHO) reports that more than 700 people have been sickened with Ebola in the Democratic Republic of Congo.
The evidence the World Health Organization (WHO) has been gathering in North Kivu — where nearly 64,000 doses have been administered — point to the vaccine being highly efficacious.
As an Ebola outbreak in a conflict-plagued region of the Democratic Republic of the Congo continues to spread after four months, there’s a glimmer of hope: An experimental Ebola vaccine appears to be helping the communities it reaches.
Should the outbreak spread more widely in cities, the scale of the outbreak could tax the available supplies of an experimental vaccine being used to help contain spread, said Peter Salama, who heads the World Health Organization’s (WHO) emergencies program.
In addition to an Ebola vaccine, the Coalition for Epidemic Preparedness Innovations is currently funding the development of vaccines for Lassa fever, Middle East respiratory syndrome, Nipah virus, and coronavirus at the Jenner Institute; and by using the same technology as the Ebola vaccine — called viral vectors — researchers can significantly reduce the time it takes to develop vaccines.